ライフサイエンスコーパス: trypanosomiasis

1 surgence in sleeping sickness (human African trypanosomiasis).

2 brucei, the causative agent of human African trypanosomiasis.

3 ed, with a particular focus on human African trypanosomiasis.

4 imization for the treatment of human African trypanosomiasis.

5 ed target for the treatment of human African trypanosomiasis.

6 osoma brucei is the causing agent of African trypanosomiasis.

7 yma is a major pathogenetic event in African trypanosomiasis.

8 nfections such as tuberculosis, malaria, and trypanosomiasis.

9 ful development of a promising drug to treat trypanosomiasis.

10 omising therapeutic target for human African trypanosomiasis.

11 tential novel drug targets for human African trypanosomiasis.

12 PTR1 may be a drug target for human African trypanosomiasis.

13 ment of new treatments against human African trypanosomiasis.

14 t and prevention of human and animal African trypanosomiasis.

15 ly reproducible mouse model of human African trypanosomiasis.

16 get for new compounds to treat human African trypanosomiasis.

17 infected animals in the acute mouse model of trypanosomiasis.

18 animals in the STIB900 acute mouse model of trypanosomiasis.

19 animals in the acute mouse model of African trypanosomiasis.

20 ion could have therapeutic potential against trypanosomiasis.

21 is definitively linked to host resistance in trypanosomiasis.

22 variant cross-specific immunity for African trypanosomiasis.

23 tory and regulatory mediators during African trypanosomiasis.

24 ng phase III clinical trials against African trypanosomiasis.

25 ibitors of therapeutic value against African trypanosomiasis.

26 mportant chemotherapeutic target for African trypanosomiasis.

27 ises the use of antifolates for treatment of trypanosomiasis.

28 imulation of the host immune response during trypanosomiasis.

29 to control tsetse flies and, hence, African trypanosomiasis.

30 mals in the STIB900 animal model for African trypanosomiasis.

31 developed for the treatment of human African trypanosomiasis.

32 es (PMCAs) of T. brucei, an agent of African trypanosomiasis.

33 r developing new serodiagnostics for African trypanosomiasis.

34 robial peptides for the treatment of African trypanosomiasis.

35 omes overcome host resistance during African trypanosomiasis.

36 onoallelic expression could be used to treat trypanosomiasis.

37 fforts to develop effective vaccines against trypanosomiasis.

38 some in vivo activity in a model of African trypanosomiasis.

39 nisms of tropical diseases leishmaniasis and trypanosomiasis.

40 ic Th-cell responses in experimental African trypanosomiasis.

41 d compound for treatment of cancer, HIV, and trypanosomiasis.

42 pment of specific drugs and vaccines against trypanosomiasis.

43 in the Excavate lineage that causes African trypanosomiasis.

44 chemotherapeutic target for the treatment of trypanosomiasis.

45 nd affecting the loss of fat mass in African trypanosomiasis.

46 pical climates and endemic diseases, notably trypanosomiasis.

47 the brain and prevent the onset of cerebral trypanosomiasis.

48 y process for the treatment of Human African Trypanosomiasis.

49 developed for the treatment of human African trypanosomiasis.

50 e dose of 20 mg kg(-1) were cured of stage 1 trypanosomiasis.

51 dose cure using acoziborole against African trypanosomiasis.

52 ific inhibitors for the treatment of African trypanosomiasis.

53 siense, the causative agent of Human African Trypanosomiasis.

54 protozoan parasite that causes human African trypanosomiasis.

55 e trypanosomes responsible for human African trypanosomiasis.

56 a in a stage 1 animal model of human African trypanosomiasis.

57 or T.b. gambiense, which cause human African trypanosomiasis.

58 treatments for both human and animal African trypanosomiasis.

59 brucei, the causative agent of human African trypanosomiasis.

60 diseases such as malaria, toxoplasmosis, and trypanosomiasis.

61 and new developments in vaccination against trypanosomiasis.

62 the parasites that cause malaria and African trypanosomiasis.

63 inidae), vectors of Human and Animal African trypanosomiasis.

64 hmaniasis, Chagas disease, and human African trypanosomiasis.

65 ackbone of the pharmacopoeia against African trypanosomiasis.

66 compounds for the treatment of human African trypanosomiasis.

67 peutic target for treatment of human African trypanosomiasis.

68 in the STIB900 mouse model for human African trypanosomiasis.

69 e blood meal of tsetse flies, the vector for trypanosomiasis.

70 ns as potential therapeutic drug targets for trypanosomiasis.

71 of the wider epidemiology of animal African trypanosomiasis.

72 ucei is the causative agent of human African trypanosomiasis.

73 development of drugs to treat human African trypanosomiasis.

74 t of a combination therapy for human African trypanosomiasis.

75 oan responsible for human and animal African trypanosomiasis.

76 osoma brucei, the causative agent of African trypanosomiasis.

77 ead for development of drugs against African trypanosomiasis.

78 al target for the treatment of human African trypanosomiasis.

79 a brucei spp. cause African human and animal trypanosomiasis, a burden on health and economy in Afric

80 re a key control component of African animal trypanosomiasis (AAT) in tsetse-infested areas of sub-Sa

81 Animal African trypanosomiasis (AAT) is a significant food security and

82 Animal African trypanosomiasis (AAT) is a significant socioeconomic bur

83 Animal African trypanosomiasis (AAT), caused by Trypanosoma congolense

84 the efficacy of treatment for human African trypanosomiasis, accurate tests that can discriminate re

85 brucei, the causative agent of human African trypanosomiasis, affects tens of thousands of sub-Sahara

86 Human African trypanosomiasis, also known as sleeping sickness, affect

87 Human African trypanosomiasis, also known as sleeping sickness, is a n

88 ucei is the causative agent of Human African Trypanosomiasis, also known as sleeping sickness.

89 c signatures characteristic of human African trypanosomiasis among 206 protein clusters.

90 serum samples from 85 patients with African trypanosomiasis and 146 control patients who had other p

91 tage or second-stage gambiense human African trypanosomiasis and a cerebrospinal fluid leucocyte coun

92 ed to the taxa responsible for human African trypanosomiasis and Chagas disease.

93 Trypanosoma brucei causes African trypanosomiasis and contains three full-length oligosacc

94 to diseases such as malaria, leishmaniasis, trypanosomiasis and dysentery that are responsible for m

95 s TbCLK1 as a therapeutic target for African trypanosomiasis and establishes a new chemoproteomic too

96 rypanosoma brucei causes fatal human African trypanosomiasis and evades the host immune response by r

97 panosomatid species, the causative agents of trypanosomiasis and leishmaniasis, are dependent on a fl

98 in the trypanosomatid parasites, which cause trypanosomiasis and leishmaniasis.

99 l as therapeutic agents for the treatment of trypanosomiasis and more recently cancer.

100 Trypanosoma brucei causes human African trypanosomiasis and regularly switches its major surface

101 Trypanosoma brucei causes human African trypanosomiasis and regularly switches its major surface

102 Trypanosoma brucei causes human African trypanosomiasis and regularly switches its major surface

103 we establish a mouse model of acute cerebral trypanosomiasis and we propose a mechanism whereby paras

104 ithin the GlaxoSmithKline HAT (Human African Trypanosomiasis) and Chagas chemical boxes, two collecti

105 hodesiense, a pathogen causing Human African Trypanosomiasis, and a validated drug target.

106 ABQ) library against the causative agents of trypanosomiasis, and cutaneous leishmaniasis, identifyin

107 causative agents of malaria, toxoplasmosis, trypanosomiasis, and leishmaniasis, contain a minimal ER

108 ucei, the protozoan parasite causing African trypanosomiasis, and the tsetse (Glossina) vector remain

109 Influenza, plague, and trypanosomiasis are classic examples of zoonotic infecti

110 All four main drugs used for human African trypanosomiasis are toxic, and melarsoprol, the only dru

111 ypanosoma brucei, which causes human African trypanosomiasis, as well as the livestock disease, nagan

112 The control of African trypanosomiasis (AT) in Eastern and Southern Africa, inc

113 ical diseases such as leprosy, human African trypanosomiasis, Buruli ulcer, and visceral leishmaniasi

114 nt option for reducing the impact of African trypanosomiasis but, although many effective methods hav

115 as new therapeutic targets for human African trypanosomiasis by both genetic and pharmacological mean

116 anti-inflammatory therapies in Human African trypanosomiasis by modulating the NK1 receptor as well a

117 cutaneous), Chagas disease and human African trypanosomiasis cause substantial death and morbidity, p

118 lected parasitic diseases, including African trypanosomiasis caused by the protozoan, Trypanosoma bru

119 Human African trypanosomiasis caused by Trypanosoma brucei gambiense i

120 n, particularly in the case of Human African Trypanosomiasis caused by Trypanosoma brucei gambiense.

121 mes in two types: East African human African trypanosomiasis caused by Trypanosoma brucei rhodesiense

122 Novel methods for treatment of African trypanosomiasis, caused by infection with Trypanosoma br

123 Human African trypanosomiasis, caused by the eukaryotic parasite Trypa

124 CBL0137 is a lead drug for human African trypanosomiasis, caused by Trypanosoma brucei Herein, we

125 African sleeping sickness or human African trypanosomiasis, caused by Trypanosoma brucei spp., is r

126 f species that cause leishmaniasis, American trypanosomiasis (Chagas disease), and African trypanosom

127 soma cruzi , the etiologic agent of American trypanosomiasis (Chagas disease), exhibiting IC(50) valu

128 ishmania spp., which in humans cause African trypanosomiasis, Chagas disease, and leishmaniasis, resp

129 parum, the causative agents of human African trypanosomiasis, Chagas disease, leishmaniasis, and mala

130 ping world, including malaria, human African trypanosomiasis, Chagas disease, leishmaniasis, filarias

131 Trypanosoma brucei causes African trypanosomiasis, colonizing adipose tissue and inducing

132 For selected causes (African trypanosomiasis, congenital syphilis, whooping cough, me

133 osoma brucei, the causative agent of African trypanosomiasis, contains a soluble, vacuolar pyrophosph

134 ber of reported cases, patients with African trypanosomiasis continue to present major challenges to

135 vivo efficacies in the acute mouse model of trypanosomiasis, curing 3/4 or 4/4 animals at 4 x 5 mg/k

136 Treatment of human African trypanosomiasis currently relies on a limited number of

137 also contribute to generating novel African trypanosomiasis disease control strategies.

138 ges resulting from an ongoing suppression of trypanosomiasis disease in cattle in an agropastoral com

139 of severe anaemia, a debilitating feature of trypanosomiasis disease, which severely constrains cattl

140 oma brucei, the etiological agent of African trypanosomiasis, disease progression can be rapid or slo

141 compounds thus shows significant promise for trypanosomiasis drug discovery.

142 are the target of the Pan African Tsetse and Trypanosomiasis Eradication Campaign (PATTEC).

143 pigs in endemic and historical human African trypanosomiasis foci in Guinea and Cote d'Ivoire, respec

144 a primary early-stage treatment for African trypanosomiasis for nearly 100 yr.

145 The progression of human African trypanosomiasis from the early hemolymphatic stage to th

146 The gambiense human African trypanosomiasis (gHAT) elimination programme in the Demo

147 d Trypanosoma brucei gambiense human African trypanosomiasis (gHAT) for elimination as a public healt

148 Gambiense human African trypanosomiasis (gHAT) is a virulent disease declining i

149 Gambiense human African trypanosomiasis (gHAT) is marked for elimination of tran

150 The diagnosis of gambiense human African trypanosomiasis (gHAT) typically involves 2 steps: a ser

151 vector-borne disease gambiense human African trypanosomiasis (gHAT, sleeping sickness) in the last tw

152 Gambiense human African trypanosomiasis (gHAT, sleeping sickness) is one of seve

153 Gambiense human African trypanosomiasis ([gHAT] sleeping sickness) is a vector-b

154 pipeline for treatment of CNS human African trypanosomiasis, giving rise to cautious optimism.

155 rug discovery pipeline for leishmaniasis and trypanosomiasis has been filling with novel chemical ent

156 fections such as malaria, leishmaniasis, and trypanosomiasis has been steadily increasing.

157 Conversely, human trypanosomiasis has reached epidemic proportions in some

158 human suffering in the form of human African trypanosomiasis (HAT) and Chagas disease.

159 Epidemics of both forms of human African trypanosomiasis (HAT) are confined to spatially stable f

160 nostic and treatment tools for human African trypanosomiasis (HAT) are limited.

161 cted tropical diseases such as human African trypanosomiasis (HAT) are prevalent primarily in tropica

162 Human African trypanosomiasis (HAT) caused by Trypanosoma brucei gambi

163 Human African trypanosomiasis (HAT) is a neglected tropical disease ca

164 Human African trypanosomiasis (HAT) is a neglected tropical disease ca

165 Human African trypanosomiasis (HAT) is a parasitic disease affecting s

166 Human African Trypanosomiasis (HAT) is a parasitic disease originating

167 Human African Trypanosomiasis (HAT) is a vector-borne disease caused b

168 Human African trypanosomiasis (HAT) or sleeping sickness is caused by

169 ypanosoma brucei, which causes human African trypanosomiasis (HAT) or sleeping sickness, accumulates

170 ucei), the causative agent for human African trypanosomiasis (HAT) or sleeping sickness.

171 Human African trypanosomiasis (HAT) still faces few therapeutic option

172 d for drug development against human African trypanosomiasis (HAT), a disease caused by Trypanosoma b

173 Human African trypanosomiasis (HAT), a major health concern in sub-Sah

174 Human African trypanosomiasis (HAT), a neglected tropical disease caus

175 ally validated drug target for human African trypanosomiasis (HAT), also called African sleeping sick

176 cei, the causative parasite of human African trypanosomiasis (HAT), also known as African sleeping si

177 Human African trypanosomiasis (HAT), also known as sleeping sickness,

178 Human African Trypanosomiasis (HAT), caused by Trypanosoma brucei, is

179 worldwide; four in particular (human African trypanosomiasis (HAT), Chagas disease, cutaneous leishma

180 The resurgence of human African trypanosomiasis (HAT), coupled with an increased inciden

181 protozoan parasites that cause human African trypanosomiasis (HAT), depend on ornithine uptake and me

182 Human African trypanosomiasis (HAT), or African sleeping sickness, is

183 eir protective effects against human African trypanosomiasis (HAT), or African sleeping sickness.

184 Human African trypanosomiasis (HAT), or sleeping sickness, is a major

185 Human African trypanosomiasis (HAT), or sleeping sickness, is caused b

186 ug target for the treatment of human African trypanosomiasis (HAT), raising interest in understanding

187 ted tropical diseases, such as human African trypanosomiasis (HAT), require novel treatments that can

188 nity, the parasites that cause human African Trypanosomiasis (HAT), Trypanosoma brucei rhodesiense an

189 serum proteomic signature for human African trypanosomiasis (HAT), using a combination of surface-en

190 ts a promising drug target for human African trypanosomiasis (HAT), which is caused by the parasitic

191 site Trypanosoma brucei causes Human African trypanosomiasis (HAT), which threatens millions of peopl

192 brucei, the causative agent of human African trypanosomiasis (HAT).

193 heir potential toward treating human African trypanosomiasis (HAT).

194 ged remain in use for treating human African trypanosomiasis (HAT).

195 which cause Chagas disease and human African trypanosomiasis (HAT).

196 Trypanosoma brucei causes human African trypanosomiasis (HAT).

197 (meningoencephalitic) stage of human African trypanosomiasis (HAT).

198 rucei causes the fatal illness human African trypanosomiasis (HAT).

199 nervous system second stage of human African trypanosomiasis (HAT).

200 as a result of protection from human African trypanosomiasis (HAT).

201 ic target for the treatment of human African trypanosomiasis (HAT).

202 Uganda has both forms of human African trypanosomiasis (HAT): the chronic gambiense disease in

203 historical focus of gambiense Human African Trypanosomiasis (HAT, sleeping sickness), a disease that

204 Trypanosoma brucei sp. causes human African trypanosomiasis (HAT; African sleeping sickness).

205 ve agent of sleeping sickness (Human African Trypanosomiasis, HAT), contains a kinetoplast with the m

206 control of sleeping sickness (human African trypanosomiasis, HAT).

207 protozoan and the causative agent of African trypanosomiasis, imports about a thousand proteins into

208 ine, which is currently being tested against trypanosomiasis in humans, and berenil, which is used in

209 anosomes both in vitro and in vivo and cures trypanosomiasis in mice.

210 and is also partially responsible for animal trypanosomiasis in Sub-Saharan Africa.

211 cause human sleeping sickness and livestock trypanosomiasis in sub-Saharan Africa.

212 plied to a use case of resistance to African trypanosomiasis in the mouse.

213 be developed for treatment of human African trypanosomiasis in the near future, increasing attention

214 esults implicate both forms of human African trypanosomiasis in the selection and persistence of othe

215 ch is used clinically to treat human African trypanosomiasis, inhibits the first step in polyamine (s

216 Trypanosomiasis is a devastating neglected tropical dise

217 African trypanosomiasis is a disease caused by Trypanosoma bruce

218 Cerebral trypanosomiasis is a severe form, but the mechanism unde

219 Human African trypanosomiasis is among the World Health Organization's

220 Relative resistance to African trypanosomiasis is based on the development of a type I

221 Human African trypanosomiasis is caused by a single-celled protozoan p

222 Human African trypanosomiasis is caused by the eukaryotic microbe Tryp

223 Human African trypanosomiasis is causing thousands of deaths every yea

224 The most threatening trypanosomiasis is Chagas disease, affecting up to 12 mi

225 Untreated trypanosomiasis is fatal and the current treatments are

226 ne control of variation in susceptibility to trypanosomiasis is known to occur in mice, where the C57

227 ecular target for treatment of human African trypanosomiasis is ornithine decarboxylase (ODC), which

228 Host resistance to African trypanosomiasis is partially dependent on an early and s

229 eatment of both human and veterinary African trypanosomiasis is still, to a large extent, dependent o

230 chemotherapy for second stage human African trypanosomiasis is unsatisfactory.

231 nt need for new drug development for African trypanosomiasis is widely recognized.

232 reatment of chronic Chagas disease (American trypanosomiasis) is the long time required to achieve co

233 osoma brucei, the causative agent of African trypanosomiasis, is characterized by its high rate of en

234 amin, traditionally used in the treatment of trypanosomiasis, is under investigation in the treatment

235 anosoma brucei, a causative agent of African trypanosomiasis, is unknown.

236 e parasite Trypanasoma brucei causes African trypanosomiasis, known as sleeping sickness in humans an

237 and model analysis show that suppression of trypanosomiasis leads to increased cattle and human popu

238 brucei, the causative agent of human African trypanosomiasis, led to the identification of substitute

239 Trypanosomiasis, leishmaniasis, and malaria are major pa

240 arasitic diseases (schistosomiasis, malaria, trypanosomiasis, leishmaniasis, and toxoplasmosis) and p

241 aturation, and Ig class switching in African trypanosomiasis may be partially regulated by unusual me

242 diabetes, cirrhosis, Chagas disease, African trypanosomiasis, melanoma, and others.

243 adenosine analogues as drugs against African trypanosomiasis, N(6)-, 2-amino-N(6)-, and N(2)-substitu

244 American Trypanosomiasis or Chagas disease is a prevalent, neglec

245 lsopp argues that those tasked with managing trypanosomiasis or committed to poverty alleviation in A

246 African animal trypanosomiasis or nagana, caused principally by infecti

247 Human African trypanosomiasis or sleeping sickness is a deadly disease

248 added to the pharmacopeia for human African trypanosomiasis (or sleeping sickness), orally dosed fex

249 American trypanosomiasis, or Chagas disease, caused by the protoz

250 American trypanosomiasis, or Chagas' disease, is the leading caus

251 Human African trypanosomiasis, or sleeping sickness, is caused by infe

252 Human African trypanosomiasis, or sleeping sickness, is caused by the

253 Human African trypanosomiasis, or sleeping sickness, is caused by the

254 veterinary wasting disease and human African trypanosomiasis, or sleeping sickness.

255 e for the fatal human disease called African trypanosomiasis, or sleeping sickness.

256 ypanosoma cruziare the major agents of human trypanosomiasis; other Trypanosomaspecies can cause huma

257 oma cruzi is the causative agent of American trypanosomiasis, otherwise known as Chagas disease.

258 the neglected tropical disease human African trypanosomiasis, otherwise known as sleeping sickness.

259 osoma brucei, the causative agent of African trypanosomiasis, possesses a bona fide member of this fa

260 brucei, the causative agent of human African trypanosomiasis, possesses non-canonical mitochondrial p

261 brucei, the causative agent of human African trypanosomiasis, possesses two fatty acid synthesis path

262 The treatment of Human African trypanosomiasis remains a major unmet health need in sub

263 d Central America, Chagas' disease (American trypanosomiasis) remains one of the most prevalent infec

264 n therapy for the treatment of human African trypanosomiasis, renewing interest in nitroheterocycle t

265 s of both early and late stage human African trypanosomiasis, representing a new lead for the develop

266 hat apoptosis could be playing a role in the trypanosomiasis resistance phenotype.

267 targets for Chagas disease and Human African Trypanosomiasis, respectively.

268 Human African trypanosomiasis (sleeping sickness) affects up to half a

269 It has been argued that the risk for trypanosomiasis (sleeping sickness), carried by tsetse f

270 brucei, the causative agent of Human African Trypanosomiasis (sleeping sickness), yet little is known

271 rypanosomiasis (Chagas disease), and African trypanosomiasis (sleeping sickness).

272 r the management of early-stage East African trypanosomiasis (sleeping sickness).

273 Gambiense human African trypanosomiasis (sleeping sickness, gHAT) is a disease t

274 site Trypanosoma brucei causes human African trypanosomiasis ("sleeping sickness") across sub-Saharan

275 African trypanosomiasis, sleeping sickness in humans or nagana i

276 resent front line drugs for treating African trypanosomiasis such as melarsoprol (Arsobal) and pentam

277 he analysis of these conflicting outcomes of trypanosomiasis suppression is used to illustrate the ne

278 hypothesis that these APOL1 variants reduce trypanosomiasis susceptibility, resulting in their posit

279 re specific marker for cure of human African trypanosomiasis than parasite DNA.

280 uch as malaria, dysentery, leishmaniasis and trypanosomiasis that are responsible for millions of dea

281 ally involved in the pathogenesis of African trypanosomiasis, the contributions to this disease of CD

282 brucei, the causative agent of human African trypanosomiasis, the NDR kinase, PK50, is expressed in p

283 the situation has improved for human African trypanosomiasis, there remains an urgent need for new me

284 ina sp.) are the vectors of human and animal trypanosomiasis throughout sub-Saharan Africa.

285 Tsetse flies transmit trypanosomiasis to humans and livestock across much of s

286 a), cryptosporidiosis (Cryptosporidium), and trypanosomiasis (Trypanosoma).

287 ysis in the causative agent of human African trypanosomiasis, Trypanosoma brucei, has already shown t

288 The causative agent of human African trypanosomiasis, Trypanosoma brucei, lacks de novo purin

289 soma brucei, the causative agent for African trypanosomiasis undergoes various stages of cellular dif

290 he pathogen causing Human and Animal African trypanosomiasis, undergoes a complex developmental progr

291 l, melarsoprol (a drug used for treatment of trypanosomiasis), upon induction of apoptosis in cell li

292 protozoan parasite that causes human African trypanosomiasis, uses antigenic variation as a major vir

293 ained from 61 patients in whom human African trypanosomiasis was cured, SL RNA detection had specific

294 a, visceral leishmaniasis, and human African trypanosomiasis, we used mathematical transmission model

295 falciparum malaria, melioidosis, and African trypanosomiasis, were reported.

296 Trypanosoma cruzi causes American trypanosomiasis, wherein 30-40% of infected individuals

297 nosoma cruzi causes Chagas disease (American trypanosomiasis), which threatens the lives of millions

298 a kinetoplastid parasite that causes African trypanosomiasis, which is fatal if left untreated.

299 es with faster progression of T.b. gambiense trypanosomiasis, while G1 associates with asymptomatic c

300 a novel test that can diagnose human African trypanosomiasis with high sensitivity and specificity.